The nuclear factor ID3 endows macrophages with a potent anti-tumour activity Journal Article


Authors: Deng, Z.; Loyher, P. L.; Lazarov, T.; Li, L.; Shen, Z.; Bhinder, B.; Yang, H.; Zhong, Y.; Alberdi, A.; Massague, J.; Sun, J. C.; Benezra, R.; Glass, C. K.; Elemento, O.; Iacobuzio-Donahue, C. A.; Geissmann, F.
Article Title: The nuclear factor ID3 endows macrophages with a potent anti-tumour activity
Abstract: Macrophage activation is controlled by a balance between activating and inhibitory receptors1-7, which protect normal tissues from excessive damage during infection8,9 but promote tumour growth and metastasis in cancer7,10. Here we report that the Kupffer cell lineage-determining factor ID3 controls this balance and selectively endows Kupffer cells with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8 T lymphoid effector cells in the liver to restrict the growth of a variety of tumours. ID3 shifts the macrophage inhibitory/activating receptor balance to promote the phagocytic and lymphoid response, at least in part by buffering the binding of the transcription factors ELK1 and E2A at the SIRPA locus. Furthermore, loss- and gain-of-function experiments demonstrate that ID3 is sufficient to confer this potent anti-tumour activity to mouse bone-marrow-derived macrophages and human induced pluripotent stem-cell-derived macrophages. Expression of ID3 is therefore necessary and sufficient to endow macrophages with the ability to form an efficient anti-tumour niche, which could be harnessed for cell therapy in cancer. The Kupffer cell lineage-determining factor ID3 selectively endows macrophages with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8+ T lymphoid effector cells to restrict the growth of a variety of tumours.
Keywords: phagocytosis; differentiation; apoptotic; stem-cells; cells; growth; induction; circulating tumor-cells; kupffer cells; loop-helix proteins; mutant p53
Journal Title: Nature
Volume: 626
Issue: 8000
ISSN: 0028-0836
Publisher: Nature Publishing Group  
Date Published: 2024-02-22
Language: English
ACCESSION: WOS:001174216600006
DOI: 10.1038/s41586-023-06950-4
PROVIDER: wos
PMCID: PMC10881399
PUBMED: 38326607
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Frederic Geissmann -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics